De acuerdo con el sistema de estadificación BCLC, 79 pacientes fueron clasificados en el estadio A (58,09%), 29 (21,32%) en el estadio B, 17 (12,50%) en el estadio C y 11 pacientes (8,09%) en el estadio D. The overall median survival time was 26.52 months (95% CI 16.7-36.3). According to the BCLC staging system, 79 patients were classified as stage A (58.09%), 29 (21.32%) stage B, 17 (12.50%) stage C and 11 patients (8.09%) as stage D. The most frequent cause of liver disease was hepatitis C infection (38.97%). The mean age of the patients was 66.62 ± 11.68 years. Survival curves were estimated using the Kaplan-Meier method and predictors of survival were identified using the Cox model. The patients were studied and managed according to usual clinical practice. The diagnosis of HCC was based on the recommendation of international guidelines. Material and methods: 136 consecutive HCC patients were prospectively included in this study. The aim of this study was to evaluate the BCLC classification in our clinical practice and to know what the prognostic value of AFP is. The value of alpha-fetoprotein (AFP) has not been properly defined. Introduction and objectives: presently, the reference staging system to evaluate the prognosis of hepatocellular carcinoma (HCC) patients is "The Barcelona Clinic Liver Cancer" (BCLC) system. Rafael Gómez-Rodríguez 1, Marta Romero-Gutiérrez 1, Tomás Artaza-Varasa 1, Concepción González-Frutos 1, Juan José Ciampi-Dopazo 2, Gema-de-la-Cruz-Pérez 1 and Juan José Sánchez-Ruano 1ġUnit of Hepatology. Valor pronóstico del sistema de estadificación "Barcelona Clinic Liver Cancer" y la alfa-fetoproteína en el carcinoma hepatocelular The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |